Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SARS-CoV-2 continues to circulate in the human population necessitating regular booster immunization for its long-term control. Ideally, vaccines should ideally not only protect against symptomatic disease, but also prevent transmission via asymptomatic shedding and cover existing and future variant...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Horvath, Dennis, Termperton, Nigel, Mayora-Neto, Martin, Da Costa, Kelly, Horlacher, Reinhold, Günther, Armin, Brosig, Alexander, Morath, Jenny, Jakobs, Barbara, Groettrup, Marcus, Hoschuetzky, Heinz, Rohayem, Jacques, ter Meulen, Jan,
स्वरूप: लेख
भाषा:अंग्रेज़ी
प्रकाशित: Philipps-Universität Marburg 2023
विषय:
Immunology
Medizin
Biotechnology
Microbiology
Medical sciences Medicine
ऑनलाइन पहुंच:पीडीएफ पूर्ण पाठ
टैग: टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
टिप्पणी देने वाले पहले व्यक्ति बनें!
आपको पहले लॉग इन होना चाहिए

समान संसाधन